Patents by Inventor Samuel Lawrie DREW

Samuel Lawrie DREW has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD73 inhibitors
    Patent number: 11931343
    Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: March 19, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Beatty, Laurent Pierre Paul Debien, Samuel Lawrie Drew, Jeremy Fournier, Rebecca Louise Grange, Steven Donald Jacob, Jenna Leigh Jeffrey, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Debashis Mandal, Jay Patrick Powers, Anh Thu Tran, Rhiannon Thomas-Tran, Xuelei Yan
  • Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
    Patent number: 11787762
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: October 17, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
  • INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF
    Publication number: 20230159466
    Abstract: The present disclosure is directed to compounds that are inhibitors of HIF-2? having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Application
    Filed: October 28, 2022
    Publication date: May 25, 2023
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy FOURNIER, Balint GAL, Clayton HARDMAN, Artur Karenovich MAILYAN, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Dongdong LIU, Guillaume MATA, Masa PODUNAVAC, Jay Patrick POWERS, Brandon Reid ROSEN, Kai YU
  • 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
    Publication number: 20230024302
    Abstract: Compounds that inhibit PI3K?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3K?.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 26, 2023
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Jeremy Thomas Andre FOURNIER, Jenna Leigh JEFFREY, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Artur Karenovich MAILYAN, Guillaume MATA, Dillon Harding MILES, Jay Patrick POWERS, Ehesan UI SHARIF, Rhiannon THOMAS-TRAN, Xuelei YAN
  • INHIBITORS OF HIF-2ALPHA
    Publication number: 20230024438
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Application
    Filed: December 3, 2020
    Publication date: January 26, 2023
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Jeremy Thomas Andre FOURNIER, Tezcan GUNEY, Steven Donald JACOB, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL, Guillaume MATA, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Xuelei YAN
  • TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA
    Publication number: 20230021476
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Application
    Filed: June 8, 2022
    Publication date: January 26, 2023
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU
  • Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2?
    Patent number: 11407712
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: August 9, 2022
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
  • CD73 INHIBITORS
    Publication number: 20210346353
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: August 26, 2019
    Publication date: November 11, 2021
    Inventors: Joel BEATTY, Laurent Pierre Paul DEBIEN, Samuel Lawrie DREW, Jeremy FOURNIER, Rebecca Louise GRANGE, Steven Donald JACOB, Jenna Leigh JEFFREY, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL, Jay Patrick POWERS, Anh Thu TRAN, Rhiannon THOMAS-TRAN, Xuelei YAN
  • TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA
    Publication number: 20210317079
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Application
    Filed: March 18, 2021
    Publication date: October 14, 2021
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU